TGF-β信号通路在骨髓增生异常综合征中作用机制的研究进展
2024-07-13刘青青李宜蔷石玉士陆海颂程纬民
刘青青 李宜蔷 石玉士 陆海颂 程纬民
基金项目:广西中医药管理局资助项目(GZZC2019058)
作者单位:1广西中医药大学研究生学院(邮编530001);2广西中医药大学第一附属医院血液内科
作者简介:刘青青(1996),女,硕士在读,主要从事血液系统疾病相关机制方面研究。E-mail:571230817@qq.com
△通信作者 E-mail:cheng5min@126.com
摘要:骨髓增生异常综合征(MDS)是一种细胞遗传学与分子遗传学高度异质性的恶性克隆性疾病,且进展为急性髓系白血病(AML)的风险极高。转化生长因子-β(TGF-β)与MDS的发病密切相关,是免疫稳态及免疫耐受的关键执行者,可抑制免疫系统许多组成部分的扩张和功能。TGF-β信号通路能调控微环境中的造血细胞及免疫细胞,抑制其发挥正常生物学功能,从而加快MDS的疾病进展。就近年来TGF-β信号通路对MDS红细胞、T淋巴细胞、自然杀伤细细胞、巨噬细胞的调控作用进行综述,以期为MDS的发病机制及治疗提供新的视角。
关键词:骨髓增生异常综合征;转化生长因子β;信号传导;免疫细胞;作用机制
中图分类号:R552文献标志码:ADOI:10.11958/20231620
Research progress on the mechanism of the TGF-β signaling pathway in
myelodysplastic syndrome
LIU Qingqing1, LI Yiqiang1, SHI Yushi1, LU Haisong2, CHENG Weimin2△
1 Graduate School of Guangxi University of Traditional Chinese Medicine, Nanning 530001, China; 2 Department of
Hematology, First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine
△Corresponding Author E-mail: cheng5min@126.com
Abstract: Myelodysplastic syndrome (MDS) is a malignant clonal disease with high heterogeneity in cytogenetics and molecular genetics, and the risk of progression to acute myeloid leukemia (AML) is extremely high. Transforming growth factor-β (TGF-β) is closely related to the pathogenesis of MDS. It is a key executor of immune homeostasis and immune tolerance, and can inhibit the expansion and function of many components of immune system. TGF-β signaling pathway can regulate hematopoietic cells and immune cells in microenvironment, inhibit their normal biological functions, and thus accelerate the progression of MDS. This study reviews regulatory effects of TGF-β signaling pathway on MDS blood cells, T lymphocytes, natural killer cells and macrophages in recent years, and provides a new perspective for the pathogenesis and treatment of MDS.
Key words: myelodysplastic syndromes; transforming growth factor beta; signal transduction; immune cells; mechanism of action
骨髓增生异常综合征(myelodysplastic syndromes,MDS)是以骨髓形态异常、全血细胞减少、免疫功能紊乱等为主要表现的异质性克隆性造血系统疾病[1]。目前针对MDS的治疗研究取得了一定的成果,但仍缺乏治愈MDS的有效方法。MDS涉及多种信号通路的调控,如转化生长因子-β(transforming growth factor β,TGF-β)[2]、核因子κB(nuclear factor kappa-B,NF-κB)[3]、丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)[4]等信号通路。TGF-β信号通路已被证实是红细胞生成的潜在调节通路,其通过上调细胞周期蛋白激酶抑制剂的活性,抑制造血干细胞的增殖分化,引起造血功能障碍[2]。……
